|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 9,228,187
What is the core claim of Patent 9,228,187?
U.S. Patent 9,228,187 covers a novel small-molecule inhibitor targeting Janus kinase 1 (JAK1). The patent claims include compositions, methods of use, and methods of manufacture for these inhibitors, aimed at treating autoimmune and inflammatory diseases. The key claims focus on a chemical structure defined by a specific core scaffold with functionalized substituents suitable for selective JAK1 inhibition.
Patent scope specifics:
- Chemical Composition: The patent specifies a class of compounds characterized by a core heteroaryl structure with various substituents at particular positions, maintaining a balance between potency and selectivity for JAK1.
- Therapeutic Application: Claims extend to methods of treating diseases such as rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease using these compounds.
- Manufacturing Methods: The patent claims include methods of synthesizing the compounds, emphasizing specific chemical steps and intermediates.
How broad are the claims?
The claims are moderate in scope, emphasizing a core chemical scaffold with specific substitutions. They do not claim all JAK inhibitors but focus on a structurally defined subset with demonstrated activity against JAK1.
- Independent Claims: Cover the chemical structure broadly, with variations on substituents.
- Dependent Claims: Add specificity, including more detailed substituent groups and specific dosing methods.
Comparison with related patents:
- The patent's scope is narrower than early-stage JAK inhibitor patents, which often claim broader classes. It rivals patents like WO2016009524, which also claim JAK inhibitors but with wider structural variations.
- Its scope overlaps with later filings targeting specific compounds for autoimmune indications, but claims keep a focused chemical definition to maintain patentability.
What does the patent landscape look like?
Key patents and filings competitive or complementary:
| Patent/Publication |
Filing Date |
Assignee |
Focus |
Scope |
| US 9,228,187 |
2014-07-30 |
Pfizer Inc. |
JAK1 inhibitors |
Structurally defined compounds; therapeutic indications |
| WO2016009524 |
2014-07-31 |
AbbVie |
JAK inhibitors |
Broader chemical class; multiple indications |
| US 9,567,406 |
2014-11-20 |
Eli Lilly |
JAK1/JAK2 inhibitors |
Similar scaffold, different substitution patterns |
The patent landscape for JAK inhibitors is crowded with multiple filings from pharmaceutical companies aiming for broad or specific protections. Multiple inventors claim compositions targeting JAK1/2 with overlapping chemical scopes.
Patent expiration and expiry:
- The patent expires in 2032, following 20 years from filing (2014), assuming no patent term adjustments.
- Freedom-to-operate (FTO) analysis involves assessing overlaps with other JAK inhibitor patents, especially for competitive compounds with similar scaffolds.
What are the key points regarding patent claims and scope?
- The claims focus on a specific heteroaryl scaffold with designated substitution points.
- They encompass both the chemical entities and methods of use, broad enough to cover a range of compounds within the specified structural bounds.
- The claims are designed to prevent copying of the core chemical structure while allowing modifications for optimization.
Summary of patent landscape insights:
- The patent claims are highly structured around a core heteroaryl scaffold, limiting their scope but providing targeted exclusivity.
- The patent sits among a dense landscape of JAK inhibitor patents, with overlapping claims in chemical structure and indications.
- Potential patent challenges could target the novelty or non-obviousness of the claimed compounds, especially in the context of existing JAK inhibitor patents.
Key Takeaways
- U.S. Patent 9,228,187 claims a specific class of JAK1 inhibitors with defined chemical structures and therapeutic applications.
- The scope is moderate, with claims covering both compounds and methods of treatment, but careful with overlapping prior art.
- The patent landscape for JAK inhibitors is extensive, with competing patents from major pharmaceutical firms.
- The patent's expiration in 2032 provides a window for commercialization and further R&D.
- Patent-specific strategies should consider the overlap with other JAK inhibitor patents and the scope of claims for freedom to operate.
FAQs
Q1: Can this patent be challenged based on prior art?
A1: Yes. The validity could be challenged if prior art documents disclose similar chemical scaffolds or methods of use, especially given the densely populated JAK inhibitor patent landscape.
Q2: What are the potential limitations of the claims?
A2: The claims are limited by the specific heteroaryl core and substituents, which may be bypassed by developing compounds outside the claimed structure.
Q3: How does the scope compare with broader JAK inhibitor patents?
A3: It is narrower, focusing on a specific chemical class, but provides solid protection for compounds with the defined heteroaryl scaffold.
Q4: Are methods of treatment covered broadly?
A4: Yes, the patent claims therapeutic uses for conditions like rheumatoid arthritis, but these are often limited to the compounds within the defined chemical scope.
Q5: What strategies can companies use to design around this patent?
A5: Developing JAK inhibitors outside the specified heteroaryl framework or with different substitution patterns can avoid infringement.
References
- U.S. Patent and Trademark Office. (2023). Patent 9,228,187. https://patft.uspto.gov/
- Wipo. (2016). WO2016009524. World Intellectual Property Organization.
- Eli Lilly and Company. (2017). US 9,567,406. United States Patent.
More… ↓
⤷ Start Trial
|
